Biotech, pharmaceutical and medtech news: clinical trials, approvals, deals and healthcare markets.
Recent data from the Bureau of Labor Statistics has uncovered a concerning trend: the number of Americans reporting disabilities has surged by 1.1 million in just the past three months. The latest figures from July show an additional 234,000 Americans have joined the ranks of those identifying as
Healthcare stocks are experiencing significant challenges as the sector’s representation in the S&P 500 has declined to its lowest level in decades. The conclusion of earnings season for major biopharmaceutical companies has revealed widespread selloffs, with investor sentiment reaching notably pessimistic levels amid regulatory uncertainties. According to
Federal health officials are moving to restrict a synthetic opioid compound derived from kratom due to serious abuse potential. The substance, 7-hydroxymitragynine (7-OH), is currently available in various consumer products despite lacking FDA approval. The Department of Health and Human Services announced their recommendation on June 29 to
The Food and Drug Administration’s leading vaccine official has stepped down from his position, according to a July 29 announcement from the Department of Health and Human Services. Dr. Vinay Prasad, who had only recently taken the role, departed citing a desire to avoid becoming a distraction to the
A recent study published in BMJ Global Health has revealed concerning findings about the World Health Organization’s private fundraising division, the WHO Foundation (WHOF). The research shows that the foundation has accumulated over $82.7 million in donations, with nearly half of this sum coming from untraceable sources. According
Pharmaceutical company Sarepta Therapeutics announced Monday evening that it will temporarily halt all shipments of its Duchenne muscular dystrophy gene therapy Elevidys across the United States, following reports of three patient deaths linked to the treatment. The company’s decision came shortly after Children’s Hospital Los Angeles suspended its
Author: Yehuda Leibler Over the past few days, Sarepta Therapeutics reminded us that in public markets, credibility is not just a nice-to-have. It is a core asset. Once lost, it is incredibly challenging to recover. In less than 48 hours, Sarepta saw its share price rise nearly 20
Many popular breakfast choices in Western countries, while convenient, may be doing more harm than good according to nutrition experts. Research shows that common breakfast items like cereals, pastries, and instant oatmeal often contain concerning levels of sugar while lacking essential nutrients like protein and fiber. A recent study examining
The increasing integration of wearable technology into everyday life presents a concerning trajectory for personal privacy and bodily autonomy. Robert F. Kennedy Jr., serving as Secretary of Health and Human Services under President Trump, has proposed a nationwide initiative promoting biometric health-tracking devices for all Americans, raising alarm among
In a significant advancement for infant healthcare in India, Dr. Reddy’s Laboratories has officially launched Beyfortus® (nirsevimab), a novel preventive treatment for Respiratory Syncytial Virus (RSV) in infants. This launch follows the April 2025 announcement of their expanded partnership with Sanofi Healthcare India Private Limited that granted Dr. Reddy’
In a notable shift from consensus, Redburn Atlantic analyst Edward Lewis has issued a rare “Sell” rating for McDonald’s stock, breaking ranks with Wall Street’s predominantly bullish outlook. The downgrade stems from growing concerns about the impact of GLP-1 weight-loss medications on consumer eating habits and
Recent social media posts from EcoHealth Alliance’s former leader Peter Daszak have sparked controversy by targeting newly appointed NIH Director Dr. Jay Bhattacharya with accusations of being “anti-science” and undermining public health. These allegations, made on June 2, 2025, appear to deflect attention from Daszak’s own controversial
